Protalix BioTherapeutics Files 8-K on Officer/Director Changes

Ticker: PLX · Form: 8-K · Filed: Apr 23, 2025 · CIK: 1006281

Protalix Biotherapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyProtalix Biotherapeutics, Inc. (PLX)
Form Type8-K
Filed DateApr 23, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: corporate-governance, officer-director-changes, filing

TL;DR

Protalix BioTherapeutics 8-K: Leadership changes and financial updates filed April 23rd.

AI Summary

Protalix BioTherapeutics, Inc. filed an 8-K on April 23, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. The filing also includes financial statements and exhibits, with the earliest event reported being April 21, 2025.

Why It Matters

This filing indicates potential shifts in the company's leadership and governance structure, which could impact strategic direction and operational oversight.

Risk Assessment

Risk Level: medium — Changes in directors or officers can signal internal shifts that may affect company strategy or stability.

Key Players & Entities

  • Protalix BioTherapeutics, Inc. (company) — Registrant
  • April 21, 2025 (date) — Earliest event reported
  • April 23, 2025 (date) — Date of report

FAQ

What specific changes occurred regarding directors or officers?

The filing indicates events related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers' but does not detail the specific individuals or changes within this 8-K header.

When was the earliest event reported in this filing?

The earliest event reported was on April 21, 2025.

What is the primary business of Protalix BioTherapeutics, Inc.?

Protalix BioTherapeutics, Inc. is in the business of BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).

In which state is Protalix BioTherapeutics, Inc. incorporated?

Protalix BioTherapeutics, Inc. is incorporated in Delaware.

What is the SEC file number for Protalix BioTherapeutics, Inc.?

The SEC file number for Protalix BioTherapeutics, Inc. is 001-33357.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 23, 2025 regarding Protalix BioTherapeutics, Inc. (PLX).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.